Litigation

Recent Posts

Federal Food, Drug, And Cosmetic Act Did Not Preclude Lanham Act Challenge That Asserted That Labeling, Marketing, And Advertising Was Misleading
Posted on 1 Jul 2014 by LexisNexis Legal Newsroom Staff

On June 12, 2014, the United States Supreme Court decided the case of POM Wonderful LLC v. Coca-Cola Co., 189 L. Ed. 2d 141 (U.S. 2014) . POM Wonderful, LLC (POM) filed its initial action against Coca-Cola asserting that the labeling, marketing, and advertising... Read More

Tags: Federal Food , Advertising , POM , POM Wonderful , and Cosmetic Act , LLC , California , POM Wonderful LLC v. Coca-Cola Co. , drug , Marketing , FDCA , Litigation , Coca-Cola , Ninth Circuit , food law , labeling , U.S. Supreme Court , torts

Norton Rose Fulbright: Certification of Damages Class Denied in ‘All Natural Fruit’ False Labeling Suit
Posted on 14 Nov 2014 by Norton Rose Fulbright

By Joshua Lichtman Updating our previous post , another federal district court has interpreted Comcast Corp. v. Behrend [ an enhanced version of this opinion is available to lexis.com subscribers ] to require plaintiffs to demonstrate a viable “means... Read More

Tags: Brazil v. Dole Packaged Foods , Comcast Corp. v. Behrend , consumer protection , California , class action , class certification , product packaging , Norton Rose Fulbright , Litigation , labeling

Glaxo Adds Safety Restrictions To Avandia Label
Posted on 9 Feb 2011 by LexisNexis Litigation Resource Community Staff

WASHINGTON, D.C. - (AP) GlaxoSmithKline PLC said Monday it has updated the labeling of its diabetes pill Avandia to include safety restrictions ordered by federal health authorities because of the drug's links to heart attack. The Food and Drug Administration... Read More

Tags: GlaxoSmith Kline , Food and Drug Administration , European Union , personal injury , FDA , diabetes drugs , Justice Department , Litigation , lawsuit , diabetes pill , labeling , Avandia , heart attack